# Empa PASS on Urinary Tract Malignancies

> **NCT03464045** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 344995 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** empagliflozin
- **DRUG:** DPP-4 inhibitors

## Key facts

- **NCT ID:** NCT03464045
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-16
- **Primary completion:** 2024-03-11
- **Final completion:** 2024-03-11
- **Target enrollment:** 344995 (ACTUAL)
- **Last updated:** 2025-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03464045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03464045, "Empa PASS on Urinary Tract Malignancies". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03464045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*